由回旋加速器生产的68Ga制备的68Ga-DOTATATE:从回旋加速器到安全性评估及神经内分泌肿瘤患者诊断效能的整合方案
本研究建立回旋加速器生产68Ga并全自动合成68Ga-DOTATATE的整合方案,产物符合欧洲药典标准,合成量20.7±1.3 GBq、表观摩尔活度518±32 GBq/μmol、65分钟完成、稳定性至少5小时。回顾性对比显示,回旋加速器与发生器来源68Ga-DOTATATE的肿瘤SUVmean或SUVmax等效,但回旋加速器来源者在肾、脾、胃壁生理摄取显著更低;作者结论支持其用于常规临床实践。
要点
- 回旋加速器生产68Ga-DOTATATE合成量20.7±1.3 GBq,表观摩尔活度518±32 GBq/μmol,65分钟完成。
- 产物符合欧洲药典68Ga-氯化物(加速器生产)溶液专论要求,配制后至少稳定5小时。
- 回旋加速器与发生器来源68Ga-DOTATATE的肿瘤SUVmean或SUVmax等效,肾、脾、胃壁生理摄取后者更低。
核心结论
- 整合回旋加速器生产可获得可靠高产的临床级68Ga-DOTATATE。
- 回旋加速器生产68Ga-DOTATATE在人体中的临床安全性和显像效能为其用于常规临床实践提供了支持证据。
研究设计与样本
- 用富集压片68Zn靶,回旋加速器质子束能量12.7 MeV、照射100分钟。
- 全自动流程采用舱内溶解系统,液体分配系统将溶解靶转移至专用热室,经基于卡盒的自动模块纯化68GaCl3并标记DOTATATE。
- 对所得示踪剂溶液进行质量控制检测;68Ga-DOTATATE内照射剂量基于大鼠生物分布实验外推。
- 对注射回旋加速器或发生器生产68Ga标记DOTATATE后行PET/CT显像的患者进行回顾性对比分析。
主要发现
- 68Ga-DOTATATE合成量20.7±1.3 GBq,合成结束时表观摩尔活度518±32 GBq/μmol,65分钟完成合成。
- 产物符合欧洲药典68Ga-氯化物(加速器生产)溶液用于放射性标记的专论要求。
- 68Ga-DOTATATE配制后至少稳定5小时。
- 用OLINDA计算的回旋加速器与发生器生产68Ga-DOTATATE剂量学大致等效。
- 回旋加速器生产68Ga-DOTATATE的肿瘤病灶SUVmean或SUVmax与发生器生产68Ga相当。
关键数值与推荐
- 68Ga-DOTATATE合成量20.7±1.3 GBq(原文报告)。
- 合成结束时表观摩尔活度518±32 GBq/μmol(原文报告)。
- 合成完成时间65分钟(原文报告)。
- 配制后稳定性至少5小时(原文报告)。
- 质子束能量12.7 MeV、照射100分钟(原文报告)。
临床怎么用
- 作者结论认为,回旋加速器生产68Ga-DOTATATE的临床安全性和显像效能为其用于常规临床实践提供了支持证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cyclotron production of 68Ga is a promising approach to supply 68Ga radiopharmaceuticals. To validate this capability, an integrated solution for a robust synthesis of 68Ga-DOTATATE prepared from cyclotron-produced 68Ga was achieved. A retrospective comparison analysis was performed on patients who underwent PET/CT imaging after injection of DOTATATE labeled with 68Ga produced by a cyclotron or eluted from a generator to demonstrate the clinical safety and diagnostic efficacy of the radiopharmaceutical as a routine standard-of-care diagnostic tool in the clinic. Methods: An enriched pressed 68Zn target was irradiated by a cyclotron with a proton beam set at 12.7 MeV for 100 min. The fully automated process uses an in-vault dissolution system in which a liquid distribution system transfers the dissolved target to a dedicated hot cell for the purification of 68GaCl3 and radiolabeling of DOTATATE using a cassette-based automated module. Quality control tests were performed on the resulting tracer solution. The internal radiation dose for 68Ga-DOTATATE was based on extrapolation from rat biodistribution experiments. A retrospective comparison analysis was performed on patients who underwent PET/CT imaging after injection of DOTATATE labeled with cyclotron- or generator-produced 68Ga. Results: The synthesis of 68Ga-DOTATATE (20.7 ± 1.3 GBq) with high apparent molar activity (518 ± 32 GBq/μmol at the end of synthesis) was completed in 65 min, and the radiopharmaceutical met the requirements specified in the European Pharmacopoeia monograph on 68Ga-chloride (accelerator-produced) solution for radiolabeling. 68Ga-DOTATATE was stable for at least 5 h after formulation. The dosimetry calculated with OLINDA for cyclotron- and generator-produced 68Ga-DOTATATE was roughly equivalent. The SUVmean or SUVmax of tumoral lesions with cyclotron-produced 68Ga-DOTATATE was equivalent to that with generator-produced 68Ga. Among physiologic uptake levels, a significant difference was found in kidneys, spleen, and stomach wall, with lower values in cyclotron-produced 68Ga-DOTATATE in all cases. Conclusion: Integrated cyclotron production achieves reliable high yields of clinical-grade 68Ga-DOTATATE. The clinical safety and imaging efficacy of cyclotron-produced 68Ga-DOTATATE in humans provide supporting evidence for its use in routine clinical practice.
引用
- Tremblay S, Beaudoin JF, Bélissant Benesty O, et al. 68Ga-DOTATATE Prepared from Cyclotron-Produced 68Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients. J Nucl Med. 2022. PMID: 35906092. doi:10.2967/jnumed.121.263768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。